Human papillomaviruses (HPV) are causative agents in ano-genital and oropharyngeal cancers. 15 The virus must reprogram host gene expression to promote infection, and E6 and E7 contribute 16 to this via targeting of cellular transcription factors including p53 and pRb, respectively. The 17 HPV16 E2 protein regulates host gene expression in U2OS cells and in this study we extend 18 these observations into TERT immortalized oral keratinocytes (NOKs) that are capable of 19 supporting late stages of the HPV16 life cycle. We observed repression of innate immune genes 20 by E2 that are also repressed by the intact HPV16 genome in NOKs. RNA-seq data identified 21 167 up and 395 downregulated genes by E2; there was a highly significant overlap of the E2 22 regulated genes with those regulated by the intact HPV16 genome in the same cell type. siRNA 23 targeting of E2 reversed repression of E2 targeted genes. The ability of E2 to repress innate 24 immune genes was confirmed in an ano-genital immortalized keratinocyte cell line, N/Tert-1. 25 We present analysis of data from The Cancer Genome Atlas (TCGA) for HPV16 positive and 26 negative head and neck cancers (HNC) suggesting that E2 plays a role in regulation of the host 27 genome in cancers. Patients with HPV16 positive HNC with a loss of E2 expression exhibit a 28 worse clinical outcome and we discuss how this could, at least partially, be related to the loss of 29 E2 host gene regulation. 30 31 Importance 32 HPV16 positive tumors that retain expression of E2 have a better clinical outcome than those 33 that have lost E2 expression. It has been suggested that this is due to a loss of E2 repression of 34 E6 and E7 expression but this is not supported by data from tumors where there is not more E6 35 3 and E7 expression in the absence of E2. Here we report that E2 regulates host gene expression 36 and place this regulation in context of the HPV16 life cycle and HPV16 positive head and neck 37 cancers (the majority of which retain E2 expression). We propose that this E2 function may play 38 an important part in the increased response of HPV16 positive cancers to radiation therapy. 39 Therefore, host gene regulation by E2 may be important for promotion of the HPV16 life cycle, 40 and also for the response of HPV16 positive tumors to radiation therapy. 41 42 43 44 High risk human papillomaviruses (HR-HPV) are etiological agents in ano-genital and 45 oropharyngeal cancers (1). HPV16 is causative in around 50% of HPV positive cervical cancers 46 (HPV+CC) and 90% of HPV positive oropharyngeal cancers (HPV+OPC), the latter of which 47 has reached epidemic proportions over the past generation (2-5). 48 Following infection, HPV DNA ultimately reaches the nucleus where cellular factors induce 49 transcription from the viral genome. The viral oncogenes E6 and E7 create an environment that 50 promotes cellular proliferation and one aspect of this manipulation is the alteration of host gene 51 transcription. E7 binds to pocket proteins pRb, p130 and p107 and blocks their functional 52 interaction with E2F transcription factors resulting in transcriptional activation of their target 53 genes (6). In addition, E7 can disrupt the DREAM complex resulting in alleviation of repression 54 of DREAM targets and activation of B-Myb target genes (7); all of these changes induced by E7 55 are proliferative for the cell. The E6 protein interacts with and mediates degradation of p53 56 blocking the ability of this protein to regulate host gene transcription in response to cellular 57 stress. E6 also interacts with p300 to disrupt the role of this protein in regulating p53 function 58 and undoubtedly disrupt the function of additional p300 target proteins (8-16). Therefore, these 59 two proteins induce a radical transcriptional reprogramming of the cell to promote the HPV life 60 cycle.
Introduction
sets. There was a striking number of innate immune genes targeted by both E2 and the entire 136 HPV16 genome in NOKs. Previously we demonstrated a targeted repression of the U-ISGF3 137 gene set by HPV16 and this repression was retained by the E2 protein by itself (Table 1) . 138 The E2 protein is over expressed in the NOKs+E2 cells compared with the levels in 139 NOKs+HPV16, as is true in previous studies investigating host gene regulation by individual 140 HPV proteins, such as E6 and E7. However, the highly significant overlap in the genes regulated 141 by E2 by itself and by the entire HPV16 genome in NOKs strongly suggests that the regulation 142 of host gene transcription by E2 is an important process in the HPV16 life cycle. 143 Given the conservation in U-ISGF3 gene repression between HPV16 E2 and the entire HPV16 144 genome, validation of the E2 RNA-seq data was focused on this gene set. The protein 145 expression of IFIT1, MX1, STAT1 and IRF9 was determined in the NOKs+E2 clonal lines lines 146 ( Fig. 2a ). In 5 of the 7 lines (1, 2, 3, 6, 7) there was a repression of MX1 and IFIT1 protein 147 levels. The upstream activators of these genes and components of the ISGF3 complex, STAT1 148 and IRF9, were also downregulated in the same clones. We selected three clones for U-ISGF3 3). Therefore, repression correlates with downregulation of their upstream regulatory factors 154 STAT1 and IRF9 ( Fig. 2a ). We next investigated expression of STAT1, IRF9 and IFN RNA 155 levels in the three clones ( Fig. 2c ). All three repressed IFN expression while NOKs+E2-1 and 156 NOKs+E2-7 had a stronger repression of STAT1 and IRF9 than in NOKs+E2-2, reflective of the Previous studies have demonstrated a role for E6 and E7 in regulation of host gene transcription, 159 including innate immune gene repression. To investigate whether these proteins also regulated 160 U-ISGF3 expression in NOKs cells pooled cell lines were generated expressing HPV16 E6 161 (NOKs+E6) and HPV16 E7 (NOKs+E7) using retrovirus transduction. In addition, we generated 162 a pooled NOKs+E2 cell line (expressing HPV16 E2), using retroviral delivery to allow a direct 163 comparison with the E6 and E7 expressing cells. The expression of the HA-tagged E7 and E2 164 proteins was confirmed by western blotting (Fig 3a, lanes 2 and 3 respectively) . We could not 165 detect the HA-tagged E6 fusion protein, presumably due to low expression levels. To confirm 166 functional E6 expression in these cells the levels of the E6 degradation target, the p53 protein, 167 were determined (Fig. 3b ). The levels of p53 protein are down in the NOKs+E6 cells compared 168 to control (compare lane 3 with lane 1) confirming functional E6 expression in these cells. All of 169 the overexpressing lines expressed the appropriate viral RNA (not shown). The protein 170 expression of two of the most repressed U-ISGF3 genes, IFIT1 and MX1, was investigated in the 171 E2, E6 and E7 expressing NOKs (Fig. 3c ). E2, E6 and E7 each downregulate expression of MX1 172 while E2 and E7 both repress IFIT1 but E6 does not. To confirm that this downregulation was 173 due to gene expression levels of the IFIT1 and MX1 genes, RT-qPCR was performed on three 174 independent RNA samples prepared from the cells and additional U-ISGF3 genes were 175 investigated ( Fig. 3d ). E2 is the strongest repressor for all of the innate immune genes 176 investigated. Reflecting the protein expression levels, E6 does not repress transcription of IFIT1. 177 We investigated the expression of IFNand STAT1, a component of IFN's downstream target 178 ISGF3 complex ( Fig. 3e ). All three viral proteins are able to repress expression of IFN to a 179 similar extent, and all three can repress expression of STAT1 although E2 is again the strongest 180 repressor. These results demonstrate that all three viral proteins can repress U-ISGF3 target 181 genes, potentially via targeting of the upstream activators of these genes, STAT1 and IFN.
182
These results also demonstrate that the downstream targeting of U-ISGF3 genes is different 183 between the viral proteins and do not exclusively depend upon the downregulation of IFNas 184 E6 does not repress IFN expression but can target downstream genes). To confirm that 185 retroviral transduction alone did not interfere with the expression of U-ISGF3 expression, the 186 levels of IFIT1 and MX1 proteins were determined in NOKs, NOKs+pOZHA (the vector used to 187 generate the E2 expressing retroviral pooled cells), NOKs+pMSCV (the vector used to generate 188 NOKs+E6 and NOKs+E7) and NOKs+pcDNA (the vector used to generate the NOKs+E2 clonal 189 lines in Fig. 1 ). Figure 3f demonstrates that there is not a significant repression of either IFIT1 or 190 MX1 with any of the vectors when compared with the expression in NOKs alone (lane 1).
191
Transcriptional repression by HPV16 E2 is reversible. 192 To investigate whether transcriptional repression by E2 is reversible, we used an siRNA 193 targeting E2 (47) in NOKs+E2-1 and NOKs+E2-7 and investigated the RNA levels of E2, IFIT1, 194 MX1 and IFN at the RNA level in NOKs+E2-1 and NOKs+E2-7 mock treated (1, 4, 7, 10), 195 siRNA E2 treated (2, 5, 8, 11) and siRNA luciferase treated (3, 6, 9, 12) (Fig. 4a ). Mock and 196 siRNA luciferase treatment resulted in identical expression levels of the genes investigated. 197 siRNA targeting E2 reduced the expression level of E2 in both clones and resulted in an increase 198 in the RNA expression of IFIT1, MX1 and IFN. Therefore, the repression by E2 is at least 199 partially reversible. Figure 2 demonstrates that IFIT1 and MX1 are over 10 fold transcriptionally 200 repressed by E2 but the levels of IFIT1 and MX1 following down regulation of E2 levels (Fig. 201 4a) increase by only 3-4 fold. This may be due to residual E2 levels present following the siRNA 202 treatment, or that more time is required for complete relief from transcriptional repression, or 203 that E2 induces a permanent epigenetic marker on the genes that results in constant repression 204 irrespective of E2 levels. These possibilities will be investigated in the future. To confirm that 205 the regulation of RNA was reflected at the protein level, western blotting for E2 and IFIT1 was 206 carried out (Fig 4b.) . As with RNA analysis, the cells were mock treated (lanes 1 and 4), treated 207 with the E2 siRNA (lanes 2 and 5) or treated with a control siRNA targeting luciferase (lanes 3 208 and 6). Forty-eight hours following siRNA treatment, protein was prepared and western blotting 209 carried out. The siRNA targeting E2 attenuated expression of this protein (middle panel) and this 210 downregulation corresponded with an increase in IFIT1 protein levels (upper panel). This 211 observation was reproducible. To confirm that the increased expression of IFIT1 and MX1 in the 212 NOKs+E2 cells following downregulation of E2 expression was not due to an off target effect of 213 the siRNA we repeated these experiments in NOKs ( Fig. 4c ). None of the treatments resulted in 214 altered MX1 and IFIT1 expression levels demonstrating that there is no off target effect of the E2 215 siRNA that alters MX1 or IFIT1 expression.
216
One mechanism that HPV16 utilizes to regulate host gene transcription is to methylate host DNA 217 (48). To investigate whether the E2 protein was regulating transcription from the host genome 218 using this mechanism we treated cells with Decitabine (5-aza-2-deoxycytidine), a drug that 219 reverses DNA methylation (49). The RNA levels of IFIT1 and MX1 and the upstream regulators 220 STAT1, IRF9 and IFN were investigated following Decitabine treatment in NOKs, NOKs+E2-221 1, NOKs+E2-7 and NOKs+HPV16 ( Fig. 5a ). For IFIT1 Decitabine treatment in NOKs results in 222 a small but significant increase in RNA expression (compare lane 2 with 1) while there was a 223 much stronger response to Decitabine in the presence of E2 or the HPV16 genome. The increase 224 in IFIT1 levels in the E2 clones (lanes 4 and 6) were statistically the same as that observed for 225 HPV16 (lane 8). MX1 regulation is more complex; note the MX1 figure in Fig. 5a is on a log 226 scale. Decitabine treatment resulted in a significant elevation of MX1 RNA in NOKs (compare 227 lane 2 with 1). In both E2 clones there was over an order of magnitude increase in MX1 228 following Decitabine treatment (lanes 4 and 6), significantly more than that observed in NOKs.
229
In the presence of the entire HPV16 genome there is over a two order of magnitude elevation of suggesting that methylation by E2 and the full HPV16 genome is a major mechanism used by the 237 virus for repressing expression of IFIT1. For MX1 the story is again different. While treatment 238 with Decitabine increased the expression of this protein in the E2 and HPV16 expressing cells, it 239 is not increased to levels observed in NOKs that do not express any viral protein (compare the 240 MX1 signal in lane 2 with that in 4,6 and 8). This suggests that MX1 is controlled by 241 methylation but additional repression mechanisms in cells expressing E2 and HPV16 are 242 involved. Therefore, the results in Fig. 5a & 5b suggest that methylation is not the only 243 mechanism that E2 or the entire HPV16 genome uses to repress transcription of MX1. The 244 elevated response to Decitabine for the entire genome versus the E2 clones following Decitabine 245 treatment also demonstrates that HPV16 has, in addition to E2, additional mechanisms for 246 repressing MX1 transcription. A role for E6 and E7 in this repression seems likely. STAT1, IRF9 247 and IFN RNA levels are all elevated following Decitabine treatment in NOKs, both E2 248 expressing clones and that containing the entire HPV16 genome ( Fig. 5a ). For both STAT1 and 249 IRF9 the increase in expression following Decitabine treatment is higher in the E2 clones and 250 with the HPV16 clone and the increase is similar with both E2 and HPV16. However, the fold 251 increase in IFN expression following Decitabine treatment is no different between NOKs and 252 the E2 clones and cells containing HPV16. This suggests that there is not a direct role for E2 253 induced methylation in repressing these genes in the NOKs.
254
To confirm that the alleviation of repression with Decitabine was not due to a reduction in E2 255 protein levels, western blotting was carried out to determine the E2 protein levels following 256 Decitabine treatment (Figure 5b , lower panels). Decitabine actually increases the levels of the E2 257 protein, perhaps indicating that the promoter driving E2 expression is also methylated in the 258 NOKs+E2 cells.
259
HPV16 E2 can also repress host gene transcription in ano-genital keratinocytes. 260 To investigate whether the E2 protein could also regulate transcription from the host genome in 261 ano-genital keratinocytes, HPV16 E2 was over expressed in N/Tert-1 cells. N/Tert-1 were 262 generated by immortalizing foreskin keratinocytes with the telomerase enzyme (50). A retroviral 263 expression vector encoding E2 was used to generate N/Tert-1+E2. Fig. 6a demonstrates 264 expression of the E2 protein in N/Tert-1 cells (compare lane 2 with 1), and also shows that both 265 IFIT1 and MX1 protein expression levels are acutely repressed by E2 in this cell line (compare 266 lane 4 with 3 and 6 with 5). We next investigated expression of a sub-set of U-ISGF3 genes in 267 the N/Tert-1+E2 versus control cells ( Fig. 6b ) and 4 out of 5 genes were repressed by the E2 268 expression. Although IFI27 was greatly repressed by E2 in NOKs cells (Figs. 1e and 2c), it was 269 not repressed by E2 in the N/Tert-1. Finally, we investigated whether E2 could also repress 270 expression of components of the ISGF3 complex and its upstream activator IFN ( Fig. 6c ).
271
STAT1 expression is repressed by E2 in these cells but the repression of IFN expression is 272 small compared with that observed in NOKs (Fig. 2d ). The IFI27 and IFNresults demonstrate 273 that the pattern of repression of innate immune genes by E2 is not universal across all 274 keratinocyte cell types.
275
A role for E2 in regulating innate immune gene expression in HPV16 positive head and 276 neck cancers (HPV16+HNC). 277 Given the significant overlap between the E2 regulated genes with that of the entire HPV16 278 genome ( Fig. 1b) , we investigated whether the E2 regulated genes (Table S1 ) were also regulated 279 in HPV16 positive versus negative head and neck cancers. In order to do this, we divided the 280 head and neck cancer tumor gene expression data from The Cancer Genome Atlas (TCGA) into 281 HPV16 positive and HPV16 negative (HPV16+HNC versus HPV-HNC). The gene changes 282 between the HPV16 positive and negative cancers were then determined and Table 2 lists the 283 number of gene changes identified. For the E2 upregulated genes, 29 out of 167 were 284 upregulated by HPV16 in the tumor data set, and 137 of 395 E2 downregulated genes were 285 downregulated by HPV16; both of these numbers are statistically significant. Next, we divided 286 the HPV16+HNC into those that expressed E2 RNA and those that did not, {HPV16(E2+)+HNC 287 and HPV16(E2-)+HNC}, and compared gene changes versus HPV-HNC tumors. Again, Table 2 288 demonstrates that there is a significant overlap between the E2 regulated genes in NOKs and the 289 genes regulated by HPV16(E2+)+HNC and also HPV16(E2-)+HNC when compared with HPV-290 HNC. In the absence of E2 there is a reduction in the number of HPV16+HNC regulated genes 291 when compared with HPV-HNC; this may be due to the reduction of the number of tumors used 292 to generate the data (of the 60 HPV16+HNC, 16 had no E2 expression). Therefore, we cannot 293 conclude that there is a loss of E2 gene regulation following loss of E2 expression in these 294 tumors. However, it was notable that the repression of the U-ISGF3 gene set was lost following 295 the loss of E2 expression (Table 3) . These results strongly suggest that the host gene changes 296 induced by HPV16 E2 to promote the viral life cycle are physicologically relevant based on 297 similar effects manifested in HPV16+HNC. Table S2 lists the genes summarized by numbers in   298   Table 2 . that would not immortalize primary keratinocytes, such as expression of the E2 protein by itself. 311 We generated NOKs cells expressing E2, E6 and E7 proteins and focused on the expression of 312 U-ISGF3 genes. All three viral proteins can repress the upstream activator of ISGF3, IFN, 313 while E2 is the strongest repressor of STAT1 ( Fig. 3 ). E2 is also the strongest repressor of the U-314 ISGF3 target genes investigated, and E6 can only repress a sub-set of these genes. These results 315 demonstrate that there are three viral proteins that can repress innate immune genes; E2, E6 and 316 E7. The repression of these genes by E6 and E7 has been characterized previously (39) (40) (41) (42) , this is 317 the first time such an activity has been credited to E2. It is possible that the three viral proteins 318 can synergistically repress innate immune genes via different mechanisms. It is also possible 319 that, at different points in the viral life cycle, the role of the viral proteins in repression of these 320 genes in important. For example, following infection it has been suggested that during 321 establishment E2 expression is strong compared with E6 and E7 and therefore repression by E2 322 may be important during establishment of an HPV16 infection (51).
323
To characterize host gene reprograming by E2 in NOKs, we generated clonal cell lines 324 expressing this protein to be used in RNA-seq studies (Fig. 1 ). Using this approach with the 325 entire HPV16 genome, an in depth understanding of host gene regulation by HPV16 was 326 obtained and an in depth understanding of E2 host regulation was also obtained (Table S1 ).In 5 327 of the 7 E2 clones generated there was repression of ISGF3 components and U-ISGF3 targets at 328 both the transcriptional and protein levels (Fig. 2) . The reason for the failure of the two E2 329 clones that do not regulate transcription of these genes could be due to transfection of the cells at 330 different points of the cell cycle, or it may be related to actual differences in the transfected cells 331 that do not allow E2 programing of innate immune genes. To our knowledge clonal analysis of 332 E6 and E7 over expression has not been reported, therefore it is possible that this resistance to 333 reprograming may not be unique to the E2 protein. However, there is no doubt that E2 regulates 334 transcription of these host genes given the repression observed in pools of E2 expressing cells 335 from different sources ( Figs. 3 and 6) , and the ability to reverse this repression ( Figs. 4 and 5) .
336
RNA-seq analysis demonstrated a highly significant overlap between E2 regulated genes and 337 those regulated by the entire HPV16 genome in NOKs emphasizing the potential importance of 338 E2 host gene regulation during the viral life cycle. MMP9 is activated by cottontail rabbit 339 papillomavirus (CRPV) E2 protein (28), but in our data set we observed that this gene was 340 repressed by HPV16 E2. This could be due to a difference between the HPV16 and CRPV E2 341 proteins or may be related to the model systems used. The U-ISGF3 complex is also targeted for 342 repression by HPV16 E2 in the anogenital cell line N/Tert-1 (Fig. 6 ) demonstrating that this 343 repression is not something that is particular to NOKs or oral keratinocytes. The repression by 344 E2 is not identical between the two epithelial cell lines. IFN is poorly repressed by E2 in 345 N/Tert-1 but well repressed in NOKs. The U-ISGF3 target gene IFI27 is well repressed by E2 in 346 NOKs but is not repressed by E2 in N/Tert-1; if anything E2 elevates IFI27 expression in these 347 cells. These results suggest that E2 can regulate host gene transcription differently in different 348 anatomical site keratinocytes and this could have an important role in the viral life cycle in these 349 different tissues.
350
The mechanisms that E6 and E7 use for regulation of host gene transcription are at least partially 351 understood. The E2 mechanisms contributing to host gene transcription regulation are ill defined.
352
Although there are target sequences for E2 in our genome, and E2 can bind to these sequences, 353 there is no evidence that direct binding by E2 to those sequences plays a substantial role in E2 354 regulation of host gene transcription (52, 53) . We have shown that, in U2OS cells, failure to bind 355 Brd4 results in a loss of some E2 upregulated genes (54). This is presumably due to a protein-356 protein interaction recruiting E2 to Brd4 target genes. Here we demonstrate that E2 repression of 357 transcription is at least partially reversible (Fig. 4) . However, the elevation of IFIT1 and MX1 358 transcription following elimination of E2 expression via siRNA targeting is only 2-3 fold (Fig.   359 4b) whereas the repression of these genes is 10 fold and over (Fig. 2c ). This could be due to the 360 timing of the siRNA experiments, it may be that long term elimination of E2 expression would 361 result in the return of wild type IFIT1 and MX1 expression. However, the results with Decitabine 362 (Fig. 5) suggests that E2 promotes an active methylation of the repressed innate immune gene 363 promoters as repression is alleviated in the presence of this drug. The repression relief is also 364 observed in NOKs but not to the same extent as with E2. In addition to methylation, E2 also will 365 have other mechanisms for repressing transcription but the Decitabine results do suggest a partial 366 role for enhanced methylation. It may not be a direct effect on the promoters of the genes under 367 study, it could be related to a transcription factor in common to the promoters under study that is 368 regulated by E2 methylation of its gene. The Decitabine experiment also reveal a differential 369 regulation of U-ISGF3 target genes by E2 and the entire HPV16 genome. IFIT1 levels increase 370 equivalently in NOKs+E2-1, NOKs+E2-7 and NOKs+HPV16 following Decitabine treatment 371 suggesting that E2 is a major repressor of these genes during the viral life cycle. However, the 372 pattern with MX1 is different. In both E2 clones there is an order of magnitude increase in MX1 373 levels following Decitabine treatment, but in NOKs+HPV16 this is two orders of magnitude.
374
Therefore, there is differential regulation of the U-ISGF3 genes by the virus and the results with IRDS, whose increased expression predicts a worse clinical outcome in cancer. The precise 391 mechanism of how IRDS genes regulate the response to cancer therapy is not clear, however we 392 propose that loss of repression of this gene set following loss of E2 expression is at least partially 393 responsible for the worse clinical outcome in HPV16+HNC that have no E2 expression.
394
In conclusion, we have demonstrated that E2 can regulate transcription from the host genome in 395 both NOKs and N/Tert-1 although the regulation is different between the two keratinocyte cells. 396 We also provide evidence that this regulation by E2 is important in the context of the HPV16 life 397 cycle as there is a significant overlap between the E2 regulated genes and those regulated by the 398 entire HPV16 genome in NOKs. The entire HPV16 genome regulates many more host genes due Generation of NOKs+HPV16 clones was described previously (31) . N/Tert-1+E2 were prepared 425 using the plasmids described in (60) 
472
RNA-seq analysis 473 RNA sequencing was carried out by the Genomics, Epigenomics and Sequencing Core at the 474 University of Cincinnati. The methods used for RNA production and analysis to generate the 475 lists of differentially expressed genes have been described previously (31). processed for qRT-PCR or western blotting as described above. 
486

Differential Expression in NOKs
Differential Expression in TCGA
498
RNA-seq Version 2 head and neck squamous cell carcinoma (HNSC) expression data was 499 obtained from The Cancer Genome Atlas (TCGA) as described previously (46). 508 patients 500 were used for the analysis; all were either HPV16 negative (n=448) or HPV16 positive (n =60).
501
The RSEM expected counts for each patient/gene were rounded to the nearest whole number and 502 matrix was analyzed by DESeq2. Gene level analysis with default parameters was performed 503 with the same method as stated above. A Benjamini and Hochberg correction with a fixed FDR 504 of 0.001 was used and genes with expression differences >1.5 fold in magnitude were considered 505 differentially expressed.
506
Determination of E2 status for TCGA cohort 507
Unmapped human reads for 60 HPV16 positive head and neck patients from TCGA were used to 508 define raw count levels of HPV (46). Read counts were normalized by total reads/million.
509
Levels of E2 protein were defined using the HPV16 genome coordinates (K02718.1) 3625-510 3800bp as this region has no overlap between E2/E4.
511
Tumors were assigned E2 (n = 44) or no E2 (n = 16) status by plotting E2 levels and 512 determining a cut-off value based on change in slope. This method defined the no E2 group as 513 no or very little expression of E2 and E2 levels are presented in supplementary data.
514
P-value calculations for comparing gene expression changes
515
P-values for intersecting results in the bioinformatic data listed in Table 2 were obtained using 516 the hypergeometric distribution. Calculations were based on a total of 20532 genes. in NOKs. In addition, there is also a significant overlap between the E2 regulated genes and Table 3 .
Figure 1. E2 regulation of host gene expression in NOKs cells. A) Clonal cell lines were
736 generated by G418 selection following transfection with a HPV16 E2 expression plasmid and western 737 blotting for E2 carried out on cell extracts. -actin is shown as a loading control. B) RNA-seq was carried 738 out with NOKs+E2-7 alongside NOKs+HPV16 (see text for details). The numbers in the circles 739 represent the number of genes whose expression is changed 1.5 fold or greater when compared 740 with the levels in parental NOKs. The overlap between the genes regulated by NOKs+E2-7 and 741 NOKs+HPV16 are indicated as shared between the two data sets. The overlap of both the 742 upregulated and downregulated genes is highly significant as described in the text. Table S1 lists 743 the genes in each set and also those that overlap between the two samples. 
